Lonza Group AG - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
LZAGY Over the counter 2834 www.lonza.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lonza Group AG

Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market - Scalable Pharma Solutions & Generic Demand Drive $59.05 Billion Forecast for 2030 - Apr 30th, 2026 8:15 am
[Latest] Global Cell Culture Media Bags Market Size/Share Worth USD 2.28 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Apr 28th, 2026 10:30 pm
Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings? - Apr 22nd, 2026 7:10 pm
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products - Apr 21st, 2026 5:55 am
Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry - Apr 13th, 2026 8:29 am
[Latest] Global Viral Vaccine Cell Culture Media Market Size/Share Worth USD 3.5 Billion by 2035 at a 6.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Mar 10th, 2026 12:30 am
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG - Mar 6th, 2026 10:30 am
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period - Feb 3rd, 2026 5:30 am
Global Cell and Gene Therapy Manufacturing QC Market Forecast to Achieve USD 2.01 Billion by 2031: Automation and Digitalization Revolutionizing the Landscape - Jan 23rd, 2026 5:59 am
Lonza Group AG's (VTX:LONN) Intrinsic Value Is Potentially 26% Below Its Share Price - Jan 9th, 2026 11:19 pm
Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs - Jan 7th, 2026 1:30 am
GBI Biomanufacturing Announces the Appointment of Jesse McCool, Ph.D. as President - Jan 6th, 2026 6:34 am
Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum? - Oct 30th, 2025 7:45 am
Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site - Oct 23rd, 2025 3:39 am
Is Now An Opportune Moment To Examine Lonza Group AG (VTX:LONN)? - Oct 10th, 2025 1:02 am
PHG vs. LZAGY: Which Stock Is the Better Value Option? - Oct 6th, 2025 9:40 am
Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC - Sep 25th, 2025 1:30 am
Here's Why Lonza Group (LZAGY) Is a Great 'Buy the Bottom' Stock Now - Sep 22nd, 2025 7:55 am
Lonza Group AG's (VTX:LONN) 3.4% loss last week hit both individual investors who own 50% as well as institutions - Sep 16th, 2025 10:02 pm
Investors more bullish on Lonza Group (VTX:LONN) this week as stock advances 3.2%, despite earnings trending downwards over past three years - Aug 27th, 2025 12:35 am